151 related articles for article (PubMed ID: 7517796)
1. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin.
Aagaard-Tillery KM; Jelinek DF
Cell Immunol; 1994 Jul; 156(2):493-507. PubMed ID: 7517796
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of the synthesis and activity of the major cyclin-dependent kinases, p34cdc2, p33cdk2, and p34cdk4, during cell cycle entry and progression in normal human T lymphocytes.
Lucas JJ; Szepesi A; Domenico J; Tordai A; Terada N; Gelfand EW
J Cell Physiol; 1995 Nov; 165(2):406-16. PubMed ID: 7593219
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
Morice WG; Wiederrecht G; Brunn GJ; Siekierka JJ; Abraham RT
J Biol Chem; 1993 Oct; 268(30):22737-45. PubMed ID: 8226784
[TBL] [Abstract][Full Text] [Related]
4. Control of cell cycle entry and progression in mitogen-stimulated human B lymphocytes.
Takase K; Terada N; Lucas JJ; Gelfand EW
J Cell Physiol; 1995 Feb; 162(2):246-55. PubMed ID: 7529768
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug rapamycin.
Boytim ML; Lyu SC; Jung R; Krensky AM; Clayberger C
J Immunol; 1998 Mar; 160(5):2215-22. PubMed ID: 9498760
[TBL] [Abstract][Full Text] [Related]
6. The roles of T cell factors in activation, cell cycle progression, and differentiation of human B cells.
Jelinek DF; Lipsky PE
J Immunol; 1985 Mar; 134(3):1690-701. PubMed ID: 3871457
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.
Nourse J; Firpo E; Flanagan WM; Coats S; Polyak K; Lee MH; Massague J; Crabtree GR; Roberts JM
Nature; 1994 Dec; 372(6506):570-3. PubMed ID: 7990932
[TBL] [Abstract][Full Text] [Related]
8. Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine.
Gollapudi L; Neet KE
J Neurosci Res; 1997 Aug; 49(4):461-74. PubMed ID: 9285522
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets.
Songia S; Mortellaro A; Taverna S; Fornasiero C; Scheiber EA; Erba E; Colotta F; Mantovani A; Isetta AM; Golay J
J Immunol; 1997 Apr; 158(8):3987-95. PubMed ID: 9103470
[TBL] [Abstract][Full Text] [Related]
10. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.
Wicker LS; Boltz RC; Matt V; Nichols EA; Peterson LB; Sigal NH
Eur J Immunol; 1990 Oct; 20(10):2277-83. PubMed ID: 1700753
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of the immunosuppressant rapamycin.
Dumont FJ; Su Q
Life Sci; 1996; 58(5):373-95. PubMed ID: 8594303
[TBL] [Abstract][Full Text] [Related]
12. Immature stage B cells enter but do not progress beyond the early G1 phase of the cell cycle in response to antigen receptor signaling.
Carman JA; Wechsler-Reya RJ; Monroe JG
J Immunol; 1996 Jun; 156(12):4562-9. PubMed ID: 8648097
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.
Marx SO; Jayaraman T; Go LO; Marks AR
Circ Res; 1995 Mar; 76(3):412-7. PubMed ID: 7532117
[TBL] [Abstract][Full Text] [Related]
14. Impairments in both p70 S6 kinase and extracellular signal-regulated kinase signaling pathways contribute to the decline in proliferative capacity of aged hepatocytes.
Liu Y; Gorospe M; Kokkonen GC; Boluyt MO; Younes A; Mock YD; Wang X; Roth GS; Holbrook NJ
Exp Cell Res; 1998 Apr; 240(1):40-8. PubMed ID: 9570919
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle.
Terada N; Lucas JJ; Szepesi A; Franklin RA; Domenico J; Gelfand EW
J Cell Physiol; 1993 Jan; 154(1):7-15. PubMed ID: 8419408
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
17. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line.
Albers MW; Williams RT; Brown EJ; Tanaka A; Hall FL; Schreiber SL
J Biol Chem; 1993 Oct; 268(30):22825-9. PubMed ID: 8226793
[TBL] [Abstract][Full Text] [Related]
18. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation.
Calvo V; Wood M; Gjertson C; Vik T; Bierer BE
Eur J Immunol; 1994 Nov; 24(11):2664-71. PubMed ID: 7957559
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
20. The cdk2 kinase is required for the G1-to-S transition in mammalian cells.
Tsai LH; Lees E; Faha B; Harlow E; Riabowol K
Oncogene; 1993 Jun; 8(6):1593-602. PubMed ID: 8502482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
